Compare DHX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | CRBP |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.0M | 190.3M |
| IPO Year | 2007 | 2014 |
| Metric | DHX | CRBP |
|---|---|---|
| Price | $4.52 | $8.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.25 | ★ $45.50 |
| AVG Volume (30 Days) | 275.9K | ★ 577.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $127,826,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $116.00 |
| P/E Ratio | $43.00 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.44 | $7.12 |
| 52 Week High | $4.79 | $20.56 |
| Indicator | DHX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 36.08 |
| Support Level | $3.80 | $7.62 |
| Resistance Level | N/A | $9.66 |
| Average True Range (ATR) | 0.29 | 0.70 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 60.80 | 5.66 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.